nach oben

Erschienen in:

01.07.2010 | News item

FDA advisory panel votes to keep Avandia

Erschienen in: Reactions Weekly | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Excerpt

After two days of hearings, the US FDA's advisory panel has voted to allow rosiglitazone [Avandia] to remain on the market.1 …

GlaxoSmithKline.GlaxoSmithKline Statement in Response to FDA Advisory Committees′ Vote on Safety of Avandia (rosiglitazone). Media Release: 14 Jul 2010. Available from: URL: http://us.gsk.com

American Heart Association.American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy. Media Release: 14 Jul 2010. Available from: URL: http://www.americanheart.org

Parker Waichman Alonso LLP.Parker Waichman Alonso LLP Demands GlaxoSmithKline Pull Avandia from the Market Immediately Due to Company's Attempt to Hide Deadly Safety Concerns. Media Release: 14 Jul 2010. Available from: URL: http://www.businesswire.com

New York Times.Diabetes drug maker hid test data, files indicate. Internet Document: [3 pages], 12 Jul 2010. Available from: URL: http://www.nytimes.com

Titel: FDA advisory panel votes to keep Avandia
Publikationsdatum: 01.07.2010
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2010
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-201013110-00013

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Amiodarone

Voriconazole

Bisphosphonates

Heparin

Ramipril

Analgesics linked to progression of renal disease